文献速递泌尿生殖与妇科肿瘤放疗

前列腺切除术后持续PSA患者挽救放疗:大分割与常规分割比较

Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
PubMed 文献 · Radiat Oncol · 2021-05-12

中位随访67个月,大分割组(52.5 Gy/20次)较常规分割组(66 Gy/33次)无PSA失败生存更短(多因素HR 3.04,95%CI 1.37-6.74,p=0.006)。首次术后PSA和同期ADT亦与无PSA失败生存独立相关。

要点

  • 持续PSA患者中,大分割组无PSA失败生存显著劣于常规分割组(多因素HR 3.04)。
  • 首次术后PSA是治疗失败的独立危险因素(无PSA失败生存HR 1.02)。
  • 常规分割组3级晚期泌尿生殖毒性发生率为8%(3例)。

核心结论

  • 在前列腺切除术后持续PSA接受挽救放疗的患者中,常用大分割方案与较低的生化控制相关。

主要发现

  • 中位随访67个月(95%CI 58-106),5年无PSA失败生存率和无转移生存率分别为56.9%和76.9%。
  • 大分割组较常规分割组无PSA失败生存更短(单因素HR 2.2,95%CI 1.0-4.6,p=0.04;多因素HR 3.04,95%CI 1.37-6.74,p=0.006)。
  • 多因素分析中同期ADT与无PSA失败生存显著相关(HR 4.41,95%CI 1.6-12.12,p=0.004)。
  • 无转移生存的多因素分析中,首次术后PSA(HR 1.04,95%CI 1.00-1.08,p=0.02)和包膜外侵犯(HR 4.24,95%CI 1.08-16.55,p=0.04)显著相关。
  • 常规分割组3例(8%)发生3级晚期泌尿生殖毒性。

关键数值与推荐

  • 常规分割方案:66 Gy分33次,每次2 Gy。
  • 大分割方案:52.5 Gy分20次,每次2.63 Gy。
  • 持续PSA定义:前列腺切除术后PSA≥0.1 ng/mL。

临床怎么用

  • 对前列腺切除术后持续PSA患者选择挽救放疗分割方案时,需权衡大分割与常规分割的生化控制差异。
  • 首次术后PSA和包膜外侵犯等病理因素可用于风险分层。

局限性

  • 回顾性单中心设计,样本量有限。
  • 两组间ADT使用、ADT疗程和Grade Group分布存在基线不平衡。
  • 大分割组生物剂量较低可能是生化控制较差的原因,但需进一步研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypofractionated post-prostatectomy radiotherapy is emerging practice, however with no randomized evidence so far to support it's use. Additionally, patients with persistent PSA after prostatectomy may have aggressive disease and respond less well on standard salvage treatment. Herein we report outcomes for conventionally fractionated (CFR) and hypofractionated radiotherapy (HFR) in patients with persistent postprostatectomy PSA who received salvage radiotherapy to prostate bed. METHODS: Single institution retrospective chart review was performed after Institutional Review Board approval. Between May 2012 and December 2016, 147 patients received salvage postprostatectomy radiotherapy. PSA failure-free and metastasis-free survival were calculated using Kaplan-Meier method. Cox regression analysis was performed to test association of fractionation regimen and other clinical factors with treatment outcomes. Early and late toxicity was assessed using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. RESULTS: Sixty-nine patients who had persistent PSA (≥ 0.1 ng/mL) after prostatectomy were identified. Median follow-up was 67 months (95% CI 58-106 months, range, 8-106 months). Thirty-six patients (52.2%) received CFR, 66 Gy in 33 fractions, 2 Gy per fraction, and 33 patients (47.8%) received HFR, 52.5 Gy in 20 fractions, 2.63 Gy per fraction. Forty-seven (68%) patients received androgen deprivation therapy (ADT). 5-year PSA failure- and metastasis-free survival rate was 56.9% and 76.9%, respectively. Thirty patients (43%) experienced biochemical failure after salvage radiotherapy and 16 patients (23%) experienced metastatic relapse. Nine patients (13%) developed metastatic castration-resistant disease and died of advanced prostate cancer. Median PSA failure-free survival was 72 months (95% CI; 41-72 months), while median metastasis-free survival was not reached. Patients in HFR group were more likely to experience shorter PSA failure-free survival when compared to CFR group (HR 2.2; 95% CI 1.0-4.6, p = 0.04). On univariate analysis, factors significantly associated with PSA failure-free survival were radiotherapy schedule (CFR vs HFR, HR 2.2, 95% CI 1.0-4.6, p = 0.04), first postoperative PSA (HR 1.02, 95% CI 1.0-1.04, p = 0.03), and concomitant ADT (HR 3.3, 95% CI 1.2-8.6, p = 0.02). On multivariate analysis, factors significantly associated with PSA failure-free survival were radiotherapy schedule (HR 3.04, 95% CI 1.37-6.74, p = 0.006) and concomitant ADT (HR 4.41, 95% CI 1.6-12.12, p = 0.004). On univariate analysis, factors significantly associated with metastasis-free survival were the first postoperative PSA (HR 1.07, 95% CI 1.03-1.12, p = 0.002), seminal vesicle involvement (HR 3.48, 95% CI 1.26-9.6,p = 0.02), extracapsular extension (HR 7.02, 95% CI 1.96-25.07, p = 0.003), and surgical margin status (HR 2.86, 95% CI 1.03-7.97, p = 0.04). The first postoperative PSA (HR 1.04, 95% CI 1.00-1.08, p = 0.02) and extracapsular extension (HR 4.24, 95% CI 1.08-16.55, p = 0.04) remained significantly associated with metastasis-free survival on multivariate analysis. Three patients in CFR arm (8%) experienced late genitourinary grade 3 toxicity. CONCLUSIONS: In our experience, commonly used hypofractionated radiotherapy regimen was associated with lower biochemical control compared to standard fractionation in patients with persistent PSA receiving salvage radiotherapy. Reason for this might be lower biological dose in HFR compared to CFR group. However, this observation is limited due to baseline imbalances in ADT use, ADT duration and Grade Group distribution between two radiotherapy cohorts. In patients with persistent PSA post-prostatectomy, the first postoperative PSA is an independent risk factor for treatment failure. Additional studies are needed to corroborate our observations.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Murgic J, Jaksic B, Prpic M, et al. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience. Radiat Oncol. 2021. PMID: 33980277. doi:10.1186/s13014-021-01808-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。